News & Updates

Show Multimedia Only

Novel NPR-1 agonist no better than placebo for treatment of resistant hypertension

Treatment with the novel natriuretic peptide receptor-1 (NPR-1) agonist XXB750 demonstrates a neutral effect on 24-h ambulatory systolic blood pressure (SBP) in patients with resistant hypertension, as shown by the results of a phase II trial.

Novel NPR-1 agonist no better than placebo for treatment of resistant hypertension

Just Now

Asthma patients in SG show poor inhaler adherence, good disease control

1 hour ago by

Adherence to inhaler therapy among adult asthma patients in Singapore is intermediate or poor, reports a study, noting the importance of targeted interventions.

Asthma patients in SG show poor inhaler adherence, good disease control

1 hour ago

CD19 CAR T cell therapy improves QOL, cuts healthcare costs in SLE

2 hours ago

Quality of life (QOL) among patients with systemic lupus erythematosus (SLE) improves following CD19 chimeric antigen receptor (CAR) T cell therapy, with also helps lessen the socioeconomic burden associated with active disease, a study has shown.

CD19 CAR T cell therapy improves QOL, cuts healthcare costs in SLE

2 hours ago

Meta-analysis supports CAZ/AVI as Tx option for OXA-48–producing CRE

3 hours ago by

A systematic review and meta-analysis conducted by researchers in Singapore support ceftazidime-avibactam (CAZ/AVI) as a primary therapeutic alternative for the treatment of OXA-48–producing carbapenem-resistant Enterobacterales (CRE).

Meta-analysis supports CAZ/AVI as Tx option for OXA-48–producing CRE

3 hours ago

Nortriptyline misses mark in functional dyspepsia trial

19 hours ago

The tricyclic antidepressant nortriptyline is only as good as placebo in terms of reducing symptoms of functional dyspepsia in preselected patients, according to the results of a multicentre randomized controlled trial.

Nortriptyline misses mark in functional dyspepsia trial

19 hours ago

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

a day ago

Treatment with the combination of savolitinib plus osimertinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) harbouring EGFR mutation and MET amplification, as shown in the phase III SACHI trial.

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

a day ago

GLP-1RA bests aspirin for CRC prevention

06 Feb 2026 by

Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) appears to confer greater protection against the development of colorectal cancer (CRC) as compared with aspirin, according to a retrospective study.

GLP-1RA bests aspirin for CRC prevention

06 Feb 2026

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

06 Feb 2026 by

Treatment with zanidatamab combined with tislelizumab and/or chemotherapy (CT) significantly improves progression-free survival (PFS) in patients with HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA), as shown in the primary analysis from HERIZON-GEA-01.

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

06 Feb 2026

$Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma$

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

06 Feb 2026

In the treatment of patients with relapsed or refractory follicular lymphoma, adding tafasitamab to lenalidomide and rituximab appears to improve progression-free survival (PFS) while having an acceptable safety profile, according to the phase III inMIND study.

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

06 Feb 2026

CGM in diabetes: From evidence to practice

06 Feb 2026 by

Continuous glucose monitoring (CGM) is transforming diabetes care in both type 1 diabetes (T1D) and type 2 diabetes (T2D), with or without insulin use, said Dr Pratik Choudhary, Honorary Consultant and Professor at the University of Leicester, UK, during an Abbott-sponsored symposium at ATTD-Asia 2025 in Singapore.

CGM in diabetes: From evidence to practice

06 Feb 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Novel NPR-1 agonist no better than placebo for treatment of resistant hypertension

Novel NPR-1 agonist no better than placebo for treatment of resistant hypertension

Asthma patients in SG show poor inhaler adherence, good disease control

Asthma patients in SG show poor inhaler adherence, good disease control

CD19 CAR T cell therapy improves QOL, cuts healthcare costs in SLE

CD19 CAR T cell therapy improves QOL, cuts healthcare costs in SLE

Meta-analysis supports CAZ/AVI as Tx option for OXA-48–producing CRE

Meta-analysis supports CAZ/AVI as Tx option for OXA-48–producing CRE

Nortriptyline misses mark in functional dyspepsia trial

Nortriptyline misses mark in functional dyspepsia trial

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

GLP-1RA bests aspirin for CRC prevention

GLP-1RA bests aspirin for CRC prevention

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

CGM in diabetes: From evidence to practice

CGM in diabetes: From evidence to practice